3.1 RMPs & new requirements, RMP summary
3. Risk Management Plans (RMPs) / Post Authorisation Safety Studies (PASSs
New Pharmacovigilance legislation training session for patient representatives
Speaker: Stella Blackburn, Business Coordination and Scientific Projects, EMA
Видео 3.1 RMPs & new requirements, RMP summary канала European Medicines Agency
New Pharmacovigilance legislation training session for patient representatives
Speaker: Stella Blackburn, Business Coordination and Scientific Projects, EMA
Видео 3.1 RMPs & new requirements, RMP summary канала European Medicines Agency
Показать
Комментарии отсутствуют
Информация о видео
17 апреля 2013 г. 19:16:16
00:36:13
Другие видео канала
3.2 Measuring the effectiveness of RMPs
1.Overview of the EMA and the centralised procedure
Key considerations in risk-management plans
Basics - Part 14 - SUSAR Suspected Unexpected Serious Adverse Reaction
Antihypertensive Medications - Pharmacology, Animation
Module 1: Introduction to the EU Regulatory Network: Transparency, Trust and Reliance
Understanding Post-Market Surveillance Requirements under EU MDR
What is a Business Continuity Plan? PM in Under 5
Risk management plans and post-authorisation safety studies
Module 10 - Patient safety and pharmacovigilance
Pharmacovigilance Series Video 9 - Risk Management Process
Webinar on Regulatory and Procedural Aspects of Type I variations
New EU Clinical Trials Regulation: What’s New?
5.1 What is a PSUR procedure & concept of benefit-risk evaluation
GMP issues for start-ups, quality in the supply chain and role of QP
HACCP Explained
GVP (Guideline on Good Pharmacovigilance Practices)
3.3 Benefit-risk assessment throughout the lifecycle ...
Overview of the new pharmacovigilance legislation
How to write a business continuity plan